Pyxis Oncology/$PYXS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pyxis Oncology
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Ticker
$PYXS
Sector
Primary listing
Employees
56
Headquarters
Website
Pyxis Oncology Metrics
BasicAdvanced
$108m
-
-$1.28
1.42
-
Price and volume
Market cap
$108m
Beta
1.42
52-week high
$5.55
52-week low
$0.97
Average daily volume
353k
Financial strength
Current ratio
3.412
Quick ratio
3.197
Long term debt to equity
31.795
Total debt to equity
34.963
Profitability
EBITDA (TTM)
-77.334
Gross margin (TTM)
82.77%
Net profit margin (TTM)
-574.55%
Operating margin (TTM)
-590.60%
Effective tax rate (TTM)
-1.77%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-41.14%
Return on equity (TTM)
-91.43%
Valuation
Price to revenue (TTM)
7.713
Price to book
2.02
Price to tangible book (TTM)
2.02
Price to free cash flow (TTM)
-1.683
Free cash flow yield (TTM)
-59.42%
Free cash flow per share (TTM)
-1.022
Growth
Revenue change (TTM)
-14.17%
Earnings per share change (TTM)
-3.16%
3-year earnings per share growth (CAGR)
-29.49%
What the Analysts think about Pyxis Oncology
Analyst ratings (Buy, Hold, Sell) for Pyxis Oncology stock.
Pyxis Oncology Financial Performance
Revenues and expenses
Pyxis Oncology Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pyxis Oncology stock?
Pyxis Oncology (PYXS) has a market cap of $108M as of May 04, 2026.
What is the P/E ratio for Pyxis Oncology stock?
The price to earnings (P/E) ratio for Pyxis Oncology (PYXS) stock is 0 as of May 04, 2026.
Does Pyxis Oncology stock pay dividends?
No, Pyxis Oncology (PYXS) stock does not pay dividends to its shareholders as of May 04, 2026.
When is the next Pyxis Oncology dividend payment date?
Pyxis Oncology (PYXS) stock does not pay dividends to its shareholders.
What is the beta indicator for Pyxis Oncology?
Pyxis Oncology (PYXS) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.